The Commissioner’s National Priority Voucher Program (CNPV) pilot is one of the Food and Drug Administration’s (FDA) newest – and most aggressive – tools for speeding drug reviews in the name of U.S. national interests. In a new insight, Director of Health Care Policy Michael Baker explains why the high-touch review model has both promising attributes as well as practical concerns.

Key points:

• Announced in June 2025, the program offers selected sponsors a drastic reduction in review time: Instead of the standard 10–12-month clock for a new drug application or efficacy supplement, CNPV products are promised decisions in roughly 1–2 months, backed by a high-touch, multidisciplinary review process.
• Policy leaders and experts have raised concerns regarding transparency, CNPV’s legal basis, and its potential to function as a “lucrative gift” to favored companies, while warning that ultra-compressed review windows risk turning drug regulation into a series of one-off deals; the tradeoff of faster access to high-impact treatments and the procedural and governance concerns raised by a largely discretionary new pathway should both remain at the forefront of impact analysis.
• Going forward, the fate of CNPV will hinge less on how many “wins” it can claim and more on whether FDA can demonstrate that faster decisions did not come at the expense of rigor, fairness, or trust in the broader regulatory enterprise.

Read the analysis.